Top 10 Drugs Of 2020: #5 Stelara
Seizing The Opportunity In IBD
You may also be interested in...
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.